Aurobindo Pharma’s wholly owned step-down subsidiary -- CuraTeQ Biologics s.r.o. has received marketing authorization from The European Commission (EC) in the European Union for Zefylti, a filgrastim biosimilar.
Earlier in December 2024, the Committee for Medicinal Products (CHMP) of European Medicines Agency has adopted positive opinion recommending the approval of Zefylti.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
